Applied Immune Technologies' Series A Round

Applied Immune Technologies raised a round of funding on April 26, 2010. Investors include Pontifax.

Applied Immune Technologies (AIT) is a drug development company specializing in T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for a variety of therapeutic …

Articles about Applied Immune Technologies' Series A Round: